NO20073461L - Matrikstypepreparater for vedvarende frigjoring som inneholder basiske medikamenter eller salter derav, samt fremgangsmate for fremstilling derav - Google Patents
Matrikstypepreparater for vedvarende frigjoring som inneholder basiske medikamenter eller salter derav, samt fremgangsmate for fremstilling deravInfo
- Publication number
- NO20073461L NO20073461L NO20073461A NO20073461A NO20073461L NO 20073461 L NO20073461 L NO 20073461L NO 20073461 A NO20073461 A NO 20073461A NO 20073461 A NO20073461 A NO 20073461A NO 20073461 L NO20073461 L NO 20073461L
- Authority
- NO
- Norway
- Prior art keywords
- dissolution
- salt
- solution
- basic drug
- test
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004376770 | 2004-12-27 | ||
JP2005110404 | 2005-04-06 | ||
US67548205P | 2005-04-28 | 2005-04-28 | |
JP2005132338 | 2005-04-28 | ||
PCT/JP2005/023853 WO2006070781A1 (ja) | 2004-12-27 | 2005-12-27 | 塩基性薬物又はその塩を含有するマトリックス型徐放性製剤およびその製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20073461L true NO20073461L (no) | 2007-09-27 |
Family
ID=36614895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20073461A NO20073461L (no) | 2004-12-27 | 2007-07-04 | Matrikstypepreparater for vedvarende frigjoring som inneholder basiske medikamenter eller salter derav, samt fremgangsmate for fremstilling derav |
Country Status (13)
Country | Link |
---|---|
US (2) | US20090208579A1 (zh) |
EP (1) | EP1832298A4 (zh) |
JP (1) | JP4999466B2 (zh) |
KR (1) | KR100904602B1 (zh) |
CN (1) | CN103550190A (zh) |
AU (1) | AU2005320609B9 (zh) |
BR (1) | BRPI0519407A2 (zh) |
CA (1) | CA2592102C (zh) |
IL (1) | IL183871A0 (zh) |
MX (1) | MX2007007835A (zh) |
NO (1) | NO20073461L (zh) |
NZ (1) | NZ555901A (zh) |
WO (1) | WO2006070781A1 (zh) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
MX2007007836A (es) | 2004-12-27 | 2007-08-20 | Eisai R&D Man Co Ltd | Metodo para estabilizar un farmaco anti-demencia. |
CA2604052C (en) | 2005-04-06 | 2014-07-08 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of cns-related conditions |
WO2006118265A1 (ja) * | 2005-04-28 | 2006-11-09 | Eisai R & D Management Co., Ltd. | 抗痴呆薬を含有する組成物 |
EP1886670A1 (en) * | 2006-07-05 | 2008-02-13 | Teva Pharmaceutical Industries Ltd | Pharmaceutical compositions of memantine |
WO2008073282A2 (en) * | 2006-12-07 | 2008-06-19 | Schering Corporation | Ph sensitive matrix formulation |
TWI433674B (zh) | 2006-12-28 | 2014-04-11 | Infinity Discovery Inc | 環杷明(cyclopamine)類似物類 |
DE102007009242A1 (de) * | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit magensaftresistenter Wirkstoff-Matix |
EP2129677B1 (en) | 2007-03-07 | 2014-12-17 | Infinity Discovery, Inc. | Heterocyclic cyclopamine analogs and methods of use thereof |
RU2009137012A (ru) | 2007-03-07 | 2011-04-20 | Инфинити Дискавери, Инк. (Us) | Аналоги циклопаминлактама и способы их применения |
ES2717797T3 (es) | 2007-12-27 | 2019-06-25 | Infinity Pharmaceuticals Inc | Métodos para reducción estereoselectiva de derivados de 4-en-3-ona de ciclopamina |
CA2746509C (en) | 2008-12-19 | 2018-11-20 | Supernus Pharmaceuticals, Inc. | Use of molindone for the treatment of impulsive agression |
WO2010110436A1 (ja) | 2009-03-27 | 2010-09-30 | 杏林製薬株式会社 | 塩基性添加剤を含有するマトリックス型徐放性製剤 |
EP2462115B1 (en) | 2009-08-05 | 2016-01-06 | Infinity Pharmaceuticals, Inc. | Enzymatic transamination of cyclopamine analogs |
JP2011037787A (ja) * | 2009-08-13 | 2011-02-24 | Kyorin Pharmaceutical Co Ltd | 塩基性薬物のpHに依存しない安定放出組成物 |
US20110135739A1 (en) * | 2009-11-06 | 2011-06-09 | Bennett Carter | Oral Formulations of a Hedgehog Pathway Inhibitor |
JP5885668B2 (ja) | 2009-12-02 | 2016-03-15 | アダマス ファーマシューティカルズ, インコーポレイテッド | アマンタジン組成物および使用方法 |
MX2011005725A (es) * | 2010-01-26 | 2011-08-30 | Hyundai Pharm Co Ltd | Composicion farmaceutica de matriz. |
US20110218216A1 (en) * | 2010-01-29 | 2011-09-08 | Kumaravel Vivek | Extended release pharmaceutical composition of donepezil |
JP5563841B2 (ja) * | 2010-02-05 | 2014-07-30 | 沢井製薬株式会社 | 薬物の不快な味をマスキングした経口医薬組成物 |
EP2540318B1 (en) * | 2010-02-22 | 2018-10-24 | Daiichi Sankyo Company, Limited | Sustained-release solid preparation for oral use |
EP2540317A4 (en) * | 2010-02-22 | 2014-04-16 | Daiichi Sankyo Co Ltd | SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION |
EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
JP6063377B2 (ja) | 2010-03-31 | 2017-01-18 | スパーナス ファーマシューティカルズ インコーポレイテッド | Cns化合物の安定化製剤 |
WO2011127235A1 (en) * | 2010-04-07 | 2011-10-13 | Eisai Inc. | Combination therapy for the treatment of dementia |
US20120040008A1 (en) * | 2010-08-11 | 2012-02-16 | Ashish Chatterji | Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists |
US9394313B2 (en) | 2010-09-14 | 2016-07-19 | Infinity Pharmaceuticals, Inc. | Transfer hydrogenation of cyclopamine analogs |
AU2011316565A1 (en) | 2010-10-12 | 2013-05-02 | Cerecor Inc. | Antitussive compositions comprising memantine |
US20130267560A1 (en) | 2010-10-22 | 2013-10-10 | Cadila Healthcare Limited | Sustained release pharmaceutical compositions of donepezil |
WO2013033432A1 (en) * | 2011-09-03 | 2013-03-07 | Adipocyte Therapeutics Inc | Methods and compositions for treating type 2 diabetes and related conditions |
RU2665372C2 (ru) | 2012-09-03 | 2018-08-29 | Дайити Санкио Компани, Лимитед | Пероральная фармацевтическая композиция замедленного высвобождения, содержащая гидрохлорид гидроморфона |
CN105163723A (zh) * | 2013-02-28 | 2015-12-16 | 鲁平有限公司 | 具有特定体外溶解曲线或药动学参数的多奈哌齐的药物组合物 |
KR102241112B1 (ko) * | 2013-02-28 | 2021-04-15 | 루핀 리미티드 | 특정한 체외 용해 프로파일 또는 약리역학 파라미터를 갖는 도네페질의 약제학적 조성물 |
WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
AU2016271468B2 (en) | 2015-06-04 | 2020-01-02 | Sol-Gel Technologies Ltd. | Topical formulations for delivery of hedgehog inhibitor compounds and use thereof |
US20170056342A1 (en) * | 2015-08-31 | 2017-03-02 | Apotex Technologies Inc. | Extended Release Dosage Form Comprising Cyclobenzaprine Hydrochloride |
KR101938872B1 (ko) * | 2016-09-30 | 2019-01-16 | 주식회사 바이오파마티스 | 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
JP7023186B2 (ja) * | 2017-05-29 | 2022-02-21 | 第一三共株式会社 | 認知症治療薬を含有する口腔内崩壊性錠剤 |
JP6578459B1 (ja) * | 2019-02-28 | 2019-09-18 | アピ株式会社 | ハードカプセル及びその製造方法 |
KR20210072569A (ko) * | 2019-12-09 | 2021-06-17 | 주식회사 종근당 | 도네페질 및 메만틴을 포함하는 복합 제제 |
CN115876900A (zh) * | 2021-09-28 | 2023-03-31 | 江苏正大清江制药有限公司 | 一种测定克洛己新干混悬剂中盐酸溴己新溶出量的方法 |
WO2023095183A1 (en) * | 2021-11-24 | 2023-06-01 | Jordan University Of Science And Technology | A pharmaceutical composition and a solid dosage form thereof |
Family Cites Families (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HU187215B (en) * | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
IL72381A (en) * | 1983-07-20 | 1988-03-31 | Sanofi Sa | Pharmaceutical composition based on valproic acid |
US4772475A (en) * | 1985-03-08 | 1988-09-20 | Yamanouchi Pharmaceutical Co., Ltd. | Controlled-release multiple units pharmaceutical formulation |
US4892742A (en) * | 1985-11-18 | 1990-01-09 | Hoffmann-La Roche Inc. | Controlled release compositions with zero order release |
IL81419A0 (en) * | 1986-01-30 | 1987-08-31 | Syntex Inc | Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation |
US4940556A (en) * | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
NL8701335A (nl) * | 1986-06-21 | 1988-01-18 | Sandoz Ag | Orale farmaceutische preparaten. |
CA1308357C (en) * | 1987-01-28 | 1992-10-06 | Tohru Chiba | Method for the preparation of a coated solid medicament |
US4851232A (en) * | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
US4968508A (en) * | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US4894239A (en) * | 1987-06-02 | 1990-01-16 | Takeda Chemical Industries, Ltd. | Sustained-release preparation and production thereof |
US4891223A (en) * | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
JP2643222B2 (ja) * | 1988-02-03 | 1997-08-20 | エーザイ株式会社 | 多重層顆粒 |
DE3827214A1 (de) * | 1988-08-11 | 1990-02-15 | Roehm Gmbh | Retardierte arzneiform und verfahren zu ihrer herstellung |
JP2514078B2 (ja) * | 1988-08-22 | 1996-07-10 | エスエス製薬株式会社 | 圧縮成型製剤 |
JP2893191B2 (ja) * | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | 放出制御性マトリックス剤 |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
ES2077023T3 (es) * | 1989-03-10 | 1995-11-16 | Yamanouchi Pharma Co Ltd | Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada. |
NZ233403A (en) * | 1989-04-28 | 1992-09-25 | Mcneil Ppc Inc | Simulated capsule-like medicament |
US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
US5266331A (en) * | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
DE4225730C2 (de) * | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
KR950007873A (ko) * | 1993-09-20 | 1995-04-15 | 후꾸하라 요시하루 | 생리 활성 물질 지속 방출형의 의약 제제 |
US5500227A (en) * | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
US5698224A (en) * | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
US20020006438A1 (en) * | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
US5871776A (en) * | 1995-01-31 | 1999-02-16 | Mehta; Atul M. | Controlled-release nifedipine |
US6083532A (en) * | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
JPH0920663A (ja) * | 1995-07-07 | 1997-01-21 | Teikoku Seiyaku Co Ltd | イブジラストを含有する徐放性細粒剤およびその製法 |
AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
IT1282650B1 (it) * | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
US6245351B1 (en) * | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
CN1219872A (zh) * | 1996-05-24 | 1999-06-16 | 血管技术药物公司 | 治疗或预防身体通道疾病的组合物和方法 |
IT1289160B1 (it) * | 1997-01-08 | 1998-09-29 | Jagotec Ag | Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di |
DE19707655A1 (de) * | 1997-02-26 | 1998-08-27 | Hoechst Ag | Kombinationspräparat zur Anwendung bei Demenz |
CA2216215A1 (en) * | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
US6210710B1 (en) * | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
US7008950B1 (en) * | 1997-06-05 | 2006-03-07 | Takeda Chemical Industries, Ltd. | Benzofurans as suppressors of neurodegeneration |
FR2766708B1 (fr) * | 1997-07-30 | 2000-05-05 | Galenix Dev | Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention |
JP3797764B2 (ja) * | 1997-10-01 | 2006-07-19 | エーザイ株式会社 | 光安定化組成物 |
US20040028735A1 (en) * | 1997-11-14 | 2004-02-12 | Unchalee Kositprapa | Pharmaceutical formulation |
US20030092737A1 (en) * | 1997-11-14 | 2003-05-15 | Pierre Maffrand Jean | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type |
FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
US6251430B1 (en) * | 1998-02-04 | 2001-06-26 | Guohua Zhang | Water insoluble polymer based sustained release formulation |
US6372254B1 (en) * | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
DK1067910T3 (da) * | 1998-04-03 | 2004-10-04 | Egalet As | Komposition med styret afgivelse |
US6262081B1 (en) * | 1998-07-10 | 2001-07-17 | Dupont Pharmaceuticals Company | Composition for and method of treating neurological disorders |
UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
KR100746753B1 (ko) * | 1998-08-28 | 2007-08-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고미 등을 경감한 의약조성물 |
US6531152B1 (en) * | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
EP1125586A4 (en) * | 1998-10-26 | 2003-06-11 | Tanabe Seiyaku Co | EXTENDED RELEASE PARTICLES |
US6797283B1 (en) * | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
CA2358062C (en) * | 1998-12-24 | 2006-12-19 | Janssen Pharmaceutica N.V. | Controlled release galantamine composition |
EP1027887B1 (en) * | 1999-02-10 | 2008-08-13 | Pfizer Products Inc. | Matrix controlled release device |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
DE69913138T2 (de) * | 1999-03-31 | 2004-08-26 | Eisai Co., Ltd. | Stabilisierte zusammensetzung mit nootropen wirkstoffen |
ATE313319T1 (de) * | 1999-03-31 | 2006-01-15 | Janssen Pharmaceutica Nv | Vorgelatinierte stärke in einer formulierung mit gesteuerter freigabe |
US7919119B2 (en) * | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US20030124176A1 (en) * | 1999-12-16 | 2003-07-03 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
BR0007360A (pt) * | 1999-12-23 | 2001-08-14 | Johnson & Johnson | Composição de liberação controlada |
US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
AU2001239052A1 (en) * | 2000-03-06 | 2001-09-17 | Immune Network Ltd. | Compositions for prevention and treatment of dementia |
DE10029201A1 (de) * | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
GB0025208D0 (en) * | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
CA2359812C (en) * | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
SE0004671D0 (sv) * | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
CA2350195C (en) * | 2000-12-20 | 2003-06-10 | Duchesnay Inc. | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
US6287599B1 (en) * | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
US6667070B1 (en) * | 2001-02-02 | 2003-12-23 | Advanced Micro Devices, Inc. | Method of in situ monitoring of thickness and composition of deposited films using raman spectroscopy |
WO2002066004A1 (fr) * | 2001-02-23 | 2002-08-29 | Mitsubishi Pharma Corporation | Compositions a liberation controlee de medicament |
US20040022853A1 (en) * | 2001-04-26 | 2004-02-05 | Control Delivery Systems, Inc. | Polymer-based, sustained release drug delivery system |
PT1404300E (pt) * | 2001-06-22 | 2009-11-09 | Bend Res Inc | Composições farmacêuticas de dispersões de fármacos e polímeros neutros |
US6673369B2 (en) * | 2001-08-29 | 2004-01-06 | Ranbaxy Laboratories Limited | Controlled release formulation |
CA2458776A1 (en) * | 2001-08-29 | 2003-03-06 | Ashok Rampal | Controlled release formulation of clarithromycin or tinidazol |
AU2002341959A1 (en) * | 2001-10-04 | 2003-04-14 | Case Western Reserve University | Drug delivery devices and methods |
US6592901B2 (en) * | 2001-10-15 | 2003-07-15 | Hercules Incorporated | Highly compressible ethylcellulose for tableting |
AUPR839001A0 (en) * | 2001-10-19 | 2001-11-15 | Eli Lilly And Company | Dosage form, device and methods of treatment |
NZ532589A (en) * | 2001-11-07 | 2005-02-25 | Synthon Bv | Tamsulosin tablets |
AU2002358270A1 (en) * | 2001-12-20 | 2003-07-09 | Pharmacia Corporation | Zero-order sustained released dosage forms and method of making the same |
CN100340293C (zh) * | 2002-02-07 | 2007-10-03 | 卫材R&D管理有限公司 | 毛发生长促进剂、适于经皮给药的制剂 |
HRP20020124A2 (en) * | 2002-02-11 | 2003-10-31 | Pliva D D | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
DK1484056T3 (da) * | 2002-02-21 | 2013-09-08 | Otsuka Pharma Co Ltd | Sammensætninger med langsom frigivelse og fremgangsmåde til fremstilling af disse |
GB0204772D0 (en) * | 2002-02-28 | 2002-04-17 | Phoqus Ltd | Pharmaceutical dosage forms |
FR2838647B1 (fr) * | 2002-04-23 | 2006-02-17 | Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant | |
US20040005358A1 (en) * | 2002-04-23 | 2004-01-08 | Slugg Peter H. | Modified-release vasopeptidase inhibitor formulation, combinations and method |
EP1513504A1 (en) * | 2002-06-07 | 2005-03-16 | Ranbaxy Laboratories, Ltd. | Sustained release oral dosage forms of gabapentin |
IL150509A (en) * | 2002-07-01 | 2007-07-04 | Joseph Kaspi | Pharmaceutical preparations containing donafazil hydrochloride |
US20050048119A1 (en) * | 2002-09-20 | 2005-03-03 | Avinash Nangia | Controlled release composition with semi-permeable membrane and poloxamer flux enhancer |
UA83645C2 (ru) * | 2002-10-24 | 2008-08-11 | Мерц Фарма Гмбх Унд Ко. Кгаа | Фармацевтический продукт, который содержит производное 1-аминоциклогексана и ингибитор ацетилхолинестеразы, его применение |
WO2004050068A1 (en) * | 2002-11-29 | 2004-06-17 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
IL154370A0 (en) * | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
US7439365B2 (en) * | 2003-11-17 | 2008-10-21 | Usv, Ltd. | Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil) |
AR043467A1 (es) * | 2003-03-05 | 2005-07-27 | Osmotica Argentina S A | Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson |
CA2519208A1 (en) * | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Controlled release composition |
US20060210633A1 (en) * | 2003-04-03 | 2006-09-21 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
PL1638529T3 (pl) * | 2003-06-16 | 2017-03-31 | Andrx Pharmaceuticals, Llc. | Kompozycja doustna o przedłużonym uwalnianiu |
RU2375048C2 (ru) * | 2003-07-17 | 2009-12-10 | Д-Р Редди'С Лабораторис Инк. | Фармацевтическая композиция с набухающим покрытием |
US20050013863A1 (en) * | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
US20050025829A1 (en) * | 2003-07-29 | 2005-02-03 | Kim Cherng-Ju | Controlled drug release tablets |
WO2005016306A2 (en) * | 2003-08-06 | 2005-02-24 | Alza Corporation | Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation |
WO2005020957A2 (en) * | 2003-08-22 | 2005-03-10 | Alza Corporation | Stepwise delivery of topiramate over prolonged period of time |
EA200600598A1 (ru) * | 2003-09-19 | 2006-08-25 | Пенвест Фармасьютикалз Ко. | Лекарственные формы замедленного высвобождения |
EP1663145B1 (en) * | 2003-09-26 | 2011-04-06 | ALZA Corporation | Oros-push-stick for controlled delivery of active agents |
EP1523979A1 (en) * | 2003-10-13 | 2005-04-20 | Wyeth | Extended release pharmaceutical dosage form |
US20050084531A1 (en) * | 2003-10-16 | 2005-04-21 | Jatin Desai | Tablet with aqueous-based sustained release coating |
US20050129759A1 (en) * | 2003-12-16 | 2005-06-16 | Milan Sojka | Sustained release compositions and controlled delivery method |
US20050129751A1 (en) * | 2003-12-16 | 2005-06-16 | Rothenberg Barry E. | Drug delivery compositions and methods |
US20050163843A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Alprazolam formulations |
MXPA06010785A (es) * | 2004-03-26 | 2007-03-28 | Eisai R&D Man Co Ltd | Composicion farmaceutica de liberacion controlada y metodo para producir la misma. |
CN1608623A (zh) * | 2004-11-05 | 2005-04-27 | 贵州圣济堂制药有限公司 | 盐酸多奈哌齐肠溶片及其制备方法 |
US7619007B2 (en) * | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
MX2007007836A (es) * | 2004-12-27 | 2007-08-20 | Eisai R&D Man Co Ltd | Metodo para estabilizar un farmaco anti-demencia. |
US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
US20060159753A1 (en) * | 2004-12-27 | 2006-07-20 | Eisai Co. Ltd. | Matrix type sustained-release preparation containing basic drug or salt thereof |
WO2006118265A1 (ja) * | 2005-04-28 | 2006-11-09 | Eisai R & D Management Co., Ltd. | 抗痴呆薬を含有する組成物 |
CN1709229A (zh) * | 2005-06-10 | 2005-12-21 | 北京阜康仁生物制药科技有限公司 | 盐酸美金刚口腔崩解片及其制备方法 |
-
2005
- 2005-12-12 US US11/794,212 patent/US20090208579A1/en not_active Abandoned
- 2005-12-27 WO PCT/JP2005/023853 patent/WO2006070781A1/ja active Application Filing
- 2005-12-27 CN CN201310421659.XA patent/CN103550190A/zh active Pending
- 2005-12-27 BR BRPI0519407-5A patent/BRPI0519407A2/pt not_active Application Discontinuation
- 2005-12-27 MX MX2007007835A patent/MX2007007835A/es active IP Right Grant
- 2005-12-27 NZ NZ555901A patent/NZ555901A/en not_active IP Right Cessation
- 2005-12-27 CA CA2592102A patent/CA2592102C/en not_active Expired - Fee Related
- 2005-12-27 JP JP2006550780A patent/JP4999466B2/ja not_active Expired - Fee Related
- 2005-12-27 EP EP05822550A patent/EP1832298A4/en not_active Withdrawn
- 2005-12-27 AU AU2005320609A patent/AU2005320609B9/en not_active Ceased
- 2005-12-27 KR KR1020077014510A patent/KR100904602B1/ko active IP Right Grant
-
2007
- 2007-06-12 IL IL183871A patent/IL183871A0/en unknown
- 2007-07-04 NO NO20073461A patent/NO20073461L/no not_active Application Discontinuation
-
2010
- 2010-10-22 US US12/910,313 patent/US20110045074A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BRPI0519407A2 (pt) | 2009-01-20 |
IL183871A0 (en) | 2007-10-31 |
EP1832298A1 (en) | 2007-09-12 |
KR100904602B1 (ko) | 2009-06-25 |
WO2006070781A1 (ja) | 2006-07-06 |
AU2005320609A1 (en) | 2006-07-06 |
CN103550190A (zh) | 2014-02-05 |
CA2592102A1 (en) | 2006-07-06 |
US20090208579A1 (en) | 2009-08-20 |
EP1832298A4 (en) | 2012-12-12 |
CA2592102C (en) | 2012-01-24 |
JPWO2006070781A1 (ja) | 2008-06-12 |
MX2007007835A (es) | 2007-08-20 |
US20110045074A1 (en) | 2011-02-24 |
AU2005320609B2 (en) | 2009-07-02 |
KR20070089207A (ko) | 2007-08-30 |
JP4999466B2 (ja) | 2012-08-15 |
NZ555901A (en) | 2010-10-29 |
AU2005320609B9 (en) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20073461L (no) | Matrikstypepreparater for vedvarende frigjoring som inneholder basiske medikamenter eller salter derav, samt fremgangsmate for fremstilling derav | |
KR950702409A (ko) | 방출 조절 모르핀 제제(controlled release morphine preparation) | |
PE20050286A1 (es) | Formulacion de multiparticulas que comprenden oxicodona | |
BRPI0612656A8 (pt) | composição imunogênica, vacina, kit de vacina para a administração concomitante ou sequencial, processo para a produção da vacina, método de imunização de um hospedeiro humano contra doença causada por infecção de neisseria meningitidis, e, uso da composição imunogênica | |
NO20085004L (no) | Radioaktivt merkede dihydrotetrabenazinderivater og deres anvendelse som avbildningsmidler | |
WO2007128923A3 (fr) | Procede de preparation d'un gel biocompatible a libération contrôlée d'un ou de plusieurs principes actifs peu solubles dans l'eau, gels ainsi obtenus et leur utilisation | |
WO2008131149A3 (en) | Crystal forms of saxagliptin and processes for preparing same | |
MEP30008A (en) | Sustained release preparations | |
AR077453A1 (es) | Preparaciones termoestables y preparaciones insulinicas estables a las vibraciones | |
NO20064584L (no) | Tetrahydropyridoindolderivater | |
NO20081212L (no) | Xantinderivater som selektive HM74A agonister | |
DK1257577T3 (da) | Fremgangsmåde til oplösning af glucagon som peptidforbindelse | |
ATE470443T1 (de) | Indol-1-yl-essigsäurederivate | |
MXPA06010592A (es) | Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico. | |
NO20085064L (no) | 4,5-difenyl-pyrimidinyl-oksy eller -merkaptosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
NO20085066L (no) | 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
BR112015000088A8 (pt) | Composições farmacêuticas compreendendo rifamixina e aminoácidos e seus processos de preparação | |
DK1373207T3 (da) | Nyt amlodipincamsylat og fremgangsmåde til fremstilling heraf | |
NO20081681L (no) | N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika | |
NO20073549L (no) | Fremgangsmate for fremstilling av organiske forbindelser | |
NO20081785L (no) | 3-(2-dimetylaminometylcykloheksyl)fenol hemmende formulering | |
BRPI0407959A (pt) | processo para preparação de dideoxiinosina usando enzima de adenosina desaminase | |
NO20080420L (no) | Formulering med forlenget frigivelse av aktive bestanddeler med pH-avhengig loselighet | |
WO2004093867A3 (en) | Phenolic acid salts of gabapentin in liquid and/or semi-solid dosage forms and methods of use | |
RU2007128768A (ru) | Препарат матричного типа с замедленным высвобождением, содержащий основное лекарственное средство или его соль, и способ его получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |